# An Investigation of the Effect of the Promoter Polymorphism in the Glucuronosyltransferase 2B7 in Patients on Breast Cancer Treatment

> **NCT00131612** · — · TERMINATED · sponsor: **AHS Cancer Control Alberta** · enrollment: 120 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** FEC 100

## Key facts

- **NCT ID:** NCT00131612
- **Lead sponsor:** AHS Cancer Control Alberta
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2002-01
- **Primary completion:** 2005-12
- **Final completion:** 2013-01
- **Target enrollment:** 120 (ACTUAL)
- **Why stopped:** did not apply for ethics renewal
- **Last updated:** 2016-02-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00131612

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00131612, "An Investigation of the Effect of the Promoter Polymorphism in the Glucuronosyltransferase 2B7 in Patients on Breast Cancer Treatment". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT00131612. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*